FDA Clears Ciliatech IDE for US Feasibility Study of Intercil Uveal Spacer

FDA has approved Ciliatech's Investigational Device Exemption (IDE) to start a US feasibility study for the Intercil Uveal Spacer, an implant targeting primary open-angle glaucoma patients needing intervention beyond conventional minimally invasive glaucoma surgery but not yet candidates for filtering surgery.

This Wire brief sits within Fusion42's coverage of Medtech.